First Came Legal Marijuana, Now Comes…Magic Mushrooms?

Many of the places considering mushroom initiatives were also the forerunners in the marijuana decriminalization and legalization movement.

Many of the places considering mushroom initiatives were also the forerunners in the marijuana decriminalization and legalization movement. AP Photo/Peter Dejong

 

Connecting state and local government leaders

In some places where the marijuana decriminalization and legalization movement took hold, voters are being asked a new question: Should psychedelic mushrooms be next?

When Melissa Lavasani began suffering from postpartum depression after the birth of her second child, she tried a variety of treatments: talk therapy, cupping, and acupuncture. “Things were spiraling,” she said. Worried that pharmaceutical antidepressants would create a long-term dependency, she learned of a new treatment option when she listened to a podcast featuring Paul Stamets, a mycologist (fungi expert) and evangelist for the healing potential of psilocybin, the main component of magic mushrooms. 

When Lavasani tried microdosing psilocybin to treat her depression, she immediately felt better. “But it was nerve wracking,” she said. “I was well aware I was in possession of a Schedule 1 drug. I knew I was breaking the law. I was fearful I would lose my job, lose my children.”

Now Lavasani has also become an evangelist for using psilocybin for therapeutic purposes, organizing a Nov. 3 ballot initiative that asks Washington, D.C. voters to effectively decriminalize plant-based medicines. The initiative asks D.C. police to place home growing, possession, and gifting of psychedelic plants and fungi among its lowest law enforcement priorities and requests that the D.C. attorney general stop prosecuting these cases.

D.C. voters aren’t the only ones considering a hallucinogenic fungi-related ballot initiative this year. On the other side of the country, Oregon residents will weigh in on two measures: one that would decriminalize personal use of most common drugs, including magic mushrooms, and another that would create a program for the supervised, therapeutic use of psilocybin in clinical settings. If the measures pass, these places would join the ranks of Oakland, Santa Cruz, Denver, and Ann Arbor—all cities that have taken steps to decriminalize magic mushrooms in the past year.  

Many of these places were also the forerunners in the marijuana decriminalization and legalization movement. Oregon was the first state to decriminalize cannabis in 1973, while Colorado, along with Washington state, was the first to legalize recreational cannabis in 2012.  Cities like Oakland and Denver were among the first to establish functioning legal markets for the drug. The movement grew to other places, driven largely by ballot measures, with recreational pot sales allowed in 11 states and medical use of marijuana permitted in 32 states and the District of Columbia.

The gradual acceptance of marijuana set the stage for other drugs like mushrooms, said Heather Trela, a researcher who studies cannabis policy at the Rockefeller Institute of Government at the State University of New York. 

“Marijuana broke the glass ceiling,” she explained. “Legalizing that drug wasn’t the catastrophe some people were expecting. Mushroom campaigns will certainly benefit from that pathway being cleared already.”

But the measures aren’t without critics. In Oregon, for example, medical organizations have warned about the dangers of moving ahead with offering patients treatments that aren’t fully vetted by the federal government.

U.S. Rep. Andy Harris, a Maryland Republican who is one of the most vocal opponents of D.C.’s attempt to legalize marijuana, urged city voters not to take the same attitude towards psychedelics that they did towards pot. “This is a bald-faced attempt to just make these very serious, very potent, very dangerous—both short-term and long-term—hallucinogenic drugs broadly available,” Harris said in an interview with the New York Post.

Some of the factors that helped marijuana gain legal status through ballot initiatives in states across the country won’t be as helpful for mushrooms. For starters, marijuana is the most popular recreational drug on the market, with close to 35 million people defined as regular users who consume at least once a month—meaning there’s a lot of potential voters who’d like to see it legalized. The data on regular psychedelic drug users isn’t as reliable; the best estimates come from an annual survey of around 67,500 people conducted by the Substance Abuse and Mental Health Services Administration, which has found an average of 0.1% of respondents to be current psychedelic users—scaled up to the U.S. population, that’s less than 350,000 people. 

Because the potential user base is so small—and it seems unlikely to substantially increase due solely to decriminalization—ballot initiative organizers can’t make financial arguments about tax revenue, a major selling point for recreational marijuana. They also can’t make as clear an argument that psychedelic legalization is a knock against the War on Drugs, another common refrain in the pot legalization movement. (Although some researchers have argued that labeling some drugs as “good” and other drugs as “bad” inherently perpetuates the drug war.)

In places like Denver, where voters decriminalized mushrooms in 2019, only 11 cases for mushroom possession were prosecuted in the three years leading up to the ballot initiative, and numbers are similarly low in other places. “Mushrooms have never been a huge priority for law enforcement,” Trela said. “The data doesn’t exist to show disproportionate arrests of people of color in this case as it does for marijuana.”

Sam Chapman, the campaign manager for Yes on 109, one of the ballot initiatives in Oregon, said that “cannabis is not psilocybin from a historical or political context” but that “cannabis legalization helped show the general public how big a failure the War on Drugs has been.” The biggest lesson mushroom campaigns can take from marijuana legalization, he said, is ensuring that people of color have equitable access to therapy and licensing if it becomes available—a stumbling point of some marijuana legalization efforts where critics have noted that the people who have reaped the benefits of the new market have been largely white and male.

But organizers say they aren’t worried that they lack the financial and social justice arguments of the cannabis movement—because the chief benefit is the drug’s medical uses. “There’s a lot of scientific education that needs to be done for these campaigns, more so than with cannabis,” said Lavasani in D.C. “This isn’t a recreational party drug. It’s a therapy for people when no other solution works.”

A poster advertising the psychedelic ballot initiative in Washington, D.C. (Emma Coleman/Route Fifty)

Psilocybin, the naturally-occurring psychedelic component of magic mushrooms, has been utilized for thousands of years by Indigenous tribes for medicinal and spiritual purposes. (The current psychedelic movement has been criticized for failing to include Indigenous voices.) 

Clinical research and recreational use of the drug skyrocketed in the 1960s, followed by a swift crack down in 1968, when President Richard Nixon declared drugs to be “public enemy number one” and placed psychedelics like both LSD and mushrooms, along with marijuana, in the “Schedule 1” category—meaning they have “no accepted medical use” and a “high potential for abuse.”

More recently, the FDA gave psilocybin a “breakthrough therapy” designation for patients who have treatment-resistant depression, an action meant to speed drug development. Research into psilocybin has been severely stymied since the 1960s, but institutions like Johns Hopkins, Stanford, and the University of California in Los Angeles have made significant strides in recent years showing the potential uses of psilocybin in treating depression and anxiety, PTSD among veterans, and eating disorders. Researchers are hopeful about a number of other applications for diseases like smoking and drug addiction, Alzheimers, and multiple sclerosis.

That new research is changing the perception of psychedelics—but there’s still a lot of stigma, said Ismail Ali, the policy and advocacy counsel for the Multidisciplinary Association for Psychedelic Studies, a nonprofit research organization. “Right now one of the things that prevents people from publicly talking about psychedelic initiatives is because of this association with rowdy or hedonistic or non-establishment-friendly ideologies and communities,” Ali said. “There’s potential that if there's more visibility coming from [state and local initiatives], it would be easier for researchers and potential patients … to get good accurate information because it's less stigmatized to openly talk about it.”

Oregon’s Measure 109 might have the greatest chance of passing, Trela said, simply because it is so narrowly focused on the use of psilocybin in therapeutic contexts—and it therefore “cuts off slippery slope arguments.” But medical organizations have raised questions, most notably the American Psychiatric Association and the Oregon Psychiatric Physicians Association, which argue that because psilocybin therapeutic treatment is not yet approved by the FDA, the measure “makes misleading promises to Oregonians who are struggling with mental illness.” The groups warn that “determining medical treatment by ballot initiative” is unwise—and that "regulating an experimental treatment” during a pandemic will be too much for state public health officials to handle.

If the initiative does pass, mushrooms won’t be available to just anyone. The measure establishes a two-year rule making period during which state health officials would compile clinical research, create training and certification requirements, and set protective measures for patients. Therapy with psilocybin would then become a three-step process: patient screening, a psilocybin therapy session conducted under the supervision of a licensed facilitator, and a followup session to discuss the experience. 

But Nicole Cirino, a psychiatrist who is the president of the Oregon Psychiatric Physicians Association, told the Statesman Journal that as written the measure doesn’t require the person who administers psilocybin to be a doctor. "The people who are actually treating mental health in Oregon ... are not the ones supporting this measure," she said. "Wait for the science. Trust the experts."

Chapman, the measure’s campaign manager, stressed that the initiative is not approving retail sale of mushrooms, and that “no one will be taking psilocybin home with them.”

“Mental health is not a partisan issue,” Chapman said. “From terminally ill cancer patients dealing with end of life anxiety to our veterans returning home with depression, so many Oregonians stand to benefit from having access to this new breakthrough option.”

Should Oregonians choose to create the first ever statewide program for psilocybin therapy in November, Chapman said that it will set up 2022 as a “huge year” for putting mushroom propositions on the ballot. The initiative will “absolutely … set the stage for other states to follow suit,” he said.

Emma Coleman is the assistant editor for Route Fifty.

FEATURED CASE STUDIES
Powered By The Atlas
Orlando Protects Citizens During Heavy Rain Events by Optimizing Water Data Intelligence
Orlando, FL, USA
Small city of Baldwin, GA with <5K residents reduces info calls to City Hall by 50%
Baldwin, GA, USA
Green Infrastructure acts as a bridge for Indigenous reconciliation in Vancouver, BC
W 63rd Ave & Yukon St, Vancouver, BC V5X 2J2, Canada

NEXT STORY: Pennsylvania’s New Vote-by-Mail Law Expands Access for Everyone Except the Poor

X
This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Learn More / Do Not Sell My Personal Information
Accept Cookies
X
Cookie Preferences Cookie List

Do Not Sell My Personal Information

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies - Always Active

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data, Targeting & Social Media Cookies

Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link

If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences.

Targeting cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social media cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

If you want to opt out of all of our lead reports and lists, please submit a privacy request at our Do Not Sell page.

Save Settings
Cookie Preferences Cookie List

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.